Erin Mistry
Corporate Officer/Principal bei CORMEDIX INC.
Vermögen: 55 167 $ am 31.03.2024
Profil
Erin Mistry is currently the Chief Commercial Officer & Senior Vice President at CorMedix, Inc. (since 2023).
Prior to this, Mr. Mistry worked as the Vice President - Market Access at Intarcia Therapeutics, Inc.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CORMEDIX INC.
0,02% | 07.03.2024 | 13 011 ( 0,02% ) | 55 167 $ | 31.03.2024 |
Aktive Positionen von Erin Mistry
| Unternehmen | Position | Beginn |
|---|---|---|
| CORMEDIX INC. | Corporate Officer/Principal | 01.01.2020 |
Ehemalige bekannte Positionen von Erin Mistry
| Unternehmen | Position | Ende |
|---|---|---|
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CORMEDIX INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
